These results strongly support a clinical trial investigating the combination of low doses of CQ plus PI3K inhibitors and chemotherapy, allowing in the next future, an improvement of combinatorial strategies with chemotherapy in TNBC tumours. This evidence concerns the gene PIK3CA and neoplasm.